HLS Therapeutics Inc. (TSE:HLS - Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as C$5.45 and last traded at C$5.09, with a volume of 3830 shares changing hands. The stock had previously closed at C$5.03.
HLS Therapeutics Price Performance
The company has a debt-to-equity ratio of 86.50, a current ratio of 1.56 and a quick ratio of 1.01. The stock has a market cap of C$111.24 million, a P/E ratio of -5.01 and a beta of 1.07. The company's 50 day simple moving average is C$4.92 and its 200 day simple moving average is C$4.50.
HLS Therapeutics Company Profile
(
Get Free Report)
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.
Read More
Before you consider HLS Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.
While HLS Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
